Key clinical point: In updated analysis of a pivotal phase 2 study, the programmed death inhibitor cemiplimab had an increasing duration of response in patients with advanced cutaneous squamous cell carcinoma (CSCC).

Major finding: The event-free probability (no progression or death) at 20 months was 82.5% in patients with metastatic CSCC and 87.8% for locally advanced CSCC.

Study details: Update on the phase 2 EMPOWER-CSCC-1 study including 78 patients with locally advanced CSCC and 59 with metastatic CSCC treated who received weight-based intravenous cemiplimab.

Disclosures: Dr. Migden reported disclosures related to Regeneron, Novartis, Genentech, Eli Lilly, and Sun Pharmaceutical.